

**2201 SHANNON PLACE, SE
2ND FLOOR
WASHINGTON, DC 20020**

June 5, 2025

9:36 AM – 10:25 AM

**OPEN SESSION MINUTES
(WEBEX MEETING)**

Board of Pharmacy Mission Statement:

"To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians."

CALL TO ORDER: 9:37 AM

PRESIDING: DR. ALLISON HILL, PHARM.D. R.PH CHAIRPERSON

BOARD MEMBERSHIP/ATTENDANCE:

BOARD MEMBERS:		
	DR. ALLISON HILL, PHARM.D. R.PH CHAIRPERSON	PRESENT
	DR. BENJAMIN MILES, PHARM.D. R.PH	PRESENT
	DR. JAMILA JORDEN, PHARM.D. R.PH	PRESENT
	MR. RODRICK MCGILL, ESQ. CONSUMER MEMBER	LATE ARRIVAL
STAFF:		
	DR. JUSTIN ORTIQUE, PHARM.D. R.PH EXECUTIVE DIRECTOR	PRESENT
	KARIN BARRON, HEALTH LICENSING SPECIALIST	PRESENT
	LUANNE GREENAWAY, PROGRAM SPECIALIST	PRESENT
	COUNTEE GILLIAM, BOARD INVESTIGATOR	PRESENT
LEGAL STAFF:	CARLA WILLIAMS, SENIOR ASSISTANT GENERAL COUNSEL	PRESENT
VISITORS:	DR. ASHLEE BOW, FDA	
	DANIELLE DiCIOLLA	
	GAIL ELLIOTT	
	CHARLENE FAIRFAX, DEPARTMENT OF HEALTH CARE FINANCE	
	GRACE SESI, CVS HEALTH	
	JENNIFER BAUMGARTNER	
	JESSICA ADAMS, CARDINAL HEALTH	
	JESSICA COVACI	
	JOANNE DIAL, KAISER PERMANENTE	
	KARLA EVANS	
	MARCI BALOGA, SAFEWAY PHARMACY	
	NICOLE DANIELS	
	ZARIA COMER, PUBLIC	

Open Session Agenda

Quorum: Yes

Introduction:	Recognition of Dr. Ashlee Bow, PharmD. R.Ph.'s committed service as a Board Member for the DC Board of Pharmacy.	
o6o5-O-01	<p><u>Approval of the Open Session Meeting Minutes for:</u></p> <ul style="list-style-type: none">May 1, 2025 Open Session Meeting Minutes <p>Motion: Board Member, Dr. Benjamin Miles moved the Board to approve the May 1, 2025 open session meeting minutes.</p> <p>Seconded by: Dr. Jamila Jorden.</p> <p>Dr. Benjamin Miles: Voted in favor of the motion. Dr. Jamila Jorden: Voted in favor of the motion. Mr. Roderick McGill: Absent.</p> <p>Abstentions: None.</p> <p>Motion carried.</p>	
<u>Consent Agenda</u>	None	
<u>Chairperson Report</u>	<p>Establishment of Vice Chairperson of the Board</p> <ul style="list-style-type: none">Vote on Dr. Benjamin Miles as Vice Chair of the District of Columbia Board of Pharmacy. <p>Dr. Benjamin Miles: In favor of the vote. Dr. Jamila Jorden: In favor of the vote. Dr. Allison Hill: In favor of the vote.</p>	Dr. Allison Hill
<u>Office of Government Relations (OGR) Report Updates</u>	<p>FY 2026 Budget:</p> <ul style="list-style-type: none">The Local Budget for Fiscal Year 2026 for the District of Columbia Government has not yet been introduced. The Office of Government Relations (OGR) anticipates DC Health's Budget Oversight to take place in June, 2025. <p>Committee on Health Opioid Roundtable:</p> <ul style="list-style-type: none">The Committee on Health hosted a roundtable on May 7, 2025 titled "<i>The State of the District's Opioid Crisis and the Work of the Opioid Abatement Advisory Commission.</i>"<ol style="list-style-type: none">The roundtable featured testimony from the Department of Behavioral Health with support from DC Health, the Fire and	Ms. Kera Johnson

	<p>EMS Department, and the Office of the Chief Medical Examiner. The roundtable covered treatment options, harm reductions strategies and more. The roundtable can be watched at: https://www.youtube.com/live/bSI8repuBM4?si=TeF1odBhTEqOO5sU</p> <p>Certificate of Need Improvement Amendment Act</p> <ul style="list-style-type: none">▪ Councilmember Henderson introduced the Certificate of Need Improvement Amendment Act of 2025 (B26-0025) on January 6, 2025.<ul style="list-style-type: none">I. The legislation reforms the Certificate of Need (CON) process, and also establishes a new registration program for certain health facilities (including private clinics).II. The legislation also reforms the makeup and title of the Board of Integrative Healthcare.▪ The legislation was marked up out of the Committee on Health and passed the Committee of the Whole. It was signed by the Mayor and is now undergoing Congressional Review.																			
<p><u>Executive Director Report</u></p>	<p><u>Statistical Report on Pharmacy Professionals in the District of Columbia</u></p> <table><tr><td></td><td></td></tr><tr><td>PHARMACEUTICAL DETAILERS</td><td>843</td></tr><tr><td>PHARMACISTS</td><td>2,110</td></tr><tr><td>PHARMACY INTERNS</td><td>278</td></tr><tr><td>PHARMACY TECHNICIANS</td><td>1,182</td></tr><tr><td>PHARMACY TECHNICIAN TRAINEES</td><td>147</td></tr><tr><td>PHARMACISTS WITH VAC AUTHORITY</td><td>836</td></tr><tr><td>PHARMACY TECHNICIAN TRAINING PROGRAMS</td><td>15</td></tr><tr><td></td><td></td></tr></table> <p><u>Prescription Drug Monitoring Program Updates</u></p> <ul style="list-style-type: none">• All pharmacists are reminded to register for the <i>Prescription Drug Monitoring Program</i> (PDMP) within ninety (90) days of licensure in the District of Columbia, at: https://districtofcolumbia.pmpaware.net/login.• As a reminder, new licensees will receive email notifications regarding registration for the program every thirty (30) days after licensure.• Newly licensed pharmacists who fail to register for the program may be fined for non-compliance.• Pharmacists are encouraged to utilize the Delegate Option, which allows two registered pharmacy technicians to perform searches of the database on behalf of a pharmacist.			PHARMACEUTICAL DETAILERS	843	PHARMACISTS	2,110	PHARMACY INTERNS	278	PHARMACY TECHNICIANS	1,182	PHARMACY TECHNICIAN TRAINEES	147	PHARMACISTS WITH VAC AUTHORITY	836	PHARMACY TECHNICIAN TRAINING PROGRAMS	15			<p>Dr. Justin Ortique</p>
PHARMACEUTICAL DETAILERS	843																			
PHARMACISTS	2,110																			
PHARMACY INTERNS	278																			
PHARMACY TECHNICIANS	1,182																			
PHARMACY TECHNICIAN TRAINEES	147																			
PHARMACISTS WITH VAC AUTHORITY	836																			
PHARMACY TECHNICIAN TRAINING PROGRAMS	15																			

	<p><u>DCRx (DC Center for Rational Prescribing)</u></p> <ul style="list-style-type: none"> The Board is continuing its structuring of a new module titled <i>Self-Administered Hormonal Contraception</i>. More information regarding this module will be forthcoming as the process continues. <p><u>Pharmacy Facility Late License Renewal</u></p> <ul style="list-style-type: none"> The Pharmaceutical Control Division is now in its late licensure renewal period for resident and non-resident pharmacies, which ends on June 30, 2025. Pharmacies/Applicants who applied for licensure renewal on or before the close of the licensure renewal cycle (i.e. May 31, 2025) are permitted to continue doing business and/or shipping medications into the District while their application is pending. DC Health is currently processing licensure <u>renewal</u> applications from pharmacies that applied for licensure renewal before May 31, 2025. <u>Renewal in process – review pending</u> will be designated to applications for licensure renewal that were submitted on or close to the May 31, 2025 deadline and will require further review. <u>Expired - renewal eligible</u> will be designated to applications submitted after the deadline and will require further review. Pharmacies under this status <u>must wait until their license is renewed</u> to resume doing business or shipping medications into the District. <p><u>DC Board of Pharmacy Member Vacancies</u></p> <ul style="list-style-type: none"> The DC Board of Pharmacy is currently seeking two (2) licensed Pharmacists and one (1) Pharmacy Technician to fill three (3) vacancies on the Board. If you are interested in becoming a DC Board of Pharmacy member, you can apply through the Mayor’s Office of Boards and Commissions at: https://motaboards.theresumator.com/apply/1L8k6Q/Board-Of-Pharmacy. <p><u>Workplace Conditions:</u></p> <ul style="list-style-type: none"> The Pharmaceutical Control Division is currently working on rulemaking that addresses working conditions in pharmacies in the District of Columbia. At a second stakeholder meeting on May 20, 2025 a second draft of the proposed rulemaking was discussed with the intention of securing informal comments from stakeholders. The Pharmaceutical Control Division has revised the proposed rulemaking based on feedback from that meeting. 	
<p><u>Senior Assistant General</u></p>		

<u>Counsel Report</u>		
o605-O-02	None	Ms. Carla Williams
<u>Subcommittee Reports</u>		
o605-O-03	<u>Legislative and Regulatory Subcommittee Report</u> <ul style="list-style-type: none"> The Legislative and Regulatory Subcommittee report will proceed during a future scheduled open session meeting for the Board of Pharmacy. 	
o605-O-04	<u>Communications Subcommittee Report</u> <ul style="list-style-type: none"> The Communications Subcommittee report will proceed during a future scheduled open session meeting for the Board of Pharmacy. 	
<u>Pharmacy Technician Task Force</u>	<u>None</u>	
NABP E-Newsletters	<p>May 28, 2025</p> <p>Delegates Approve Six Resolutions at the 121st NABP Annual Meeting</p> <p>Kennedy Announces CDC Will No Longer Recommend COVID-19 Vaccines for Healthy Children and Pregnant Women</p> <p>Innovations: Assembling a Stronger Exam: NABP Enhancements Strengthen Pharmacy Board Competency Tools</p> <p>After COVID-19 Pandemic, Patients with OUD Enrolled in Medicaid Less Likely to Receive Telehealth Care</p> <p>Email-Related Cyberattacks Hit 180 Health Care Groups in 2024 and Early 2025</p> <p>Prescription Stimulant Misuse Common in Adults Ages 18-64</p> <p>Researchers Consider GLP-1RA Effectiveness in Treating OUD</p> <p>May 21, 2025</p> <p>NABP 2025-2026 Executive Committee Inaugurated at the 121st NABP Annual Meeting</p> <p>FDA Hosted Scientific Panel Open to Public Discussing the Future of Talc in Food, Drug, and Cosmetic Products</p>	Dr. Allison Hill

	<p>DEA's 2025 National Drug Threat Assessment Warns of Increase in Veterinary Tranquilizers Detected in Illicit Fentanyl</p> <p>Policy Perspectives: The Hidden Dangers of Alternative Funding Programs: How Cost Cutting Is Endangering Patients</p> <p>Health Care Providers Advised to Stop Administering Ixchiq Vaccine (Chikungunya Vaccine) to Individuals 60 Years and Older</p> <p>Over 620,000 Pounds of Unneeded Medications Properly Disposed of During DEA's Drug Take Back Day</p> <p>Note to the Public: To receive weekly updates from NABP, please sign up by using the following link: https://nabp.pharmacy/newsroom/news/.</p>	
<p><u>Comments from the Public</u></p>	<ul style="list-style-type: none"> • <u>Dr. Grace Sesi, CVS Health</u> requested to know if accrual of 480 hours is allowed to start while [a pharmacy student] is working as a [pharmacy intern] or do these hours begin to accrue when a pharmacy student is officially licensed as a pharmacist? <ul style="list-style-type: none"> ➤ <u>Executive Director of the DC Board of Pharmacy, Dr. Justin Ortique</u> states that the 480 hours should be completed after the pharmacy student has graduated. The intent of these hours is to allow the pharmacist to gain experience where he/she is given full responsibility. ➤ <u>Dr. Jamila Jordan, Board Member, DC Board of Pharmacy</u> agrees with Dr. Ortique's point of view by stating the hours of training grants a level of responsibility to the pharmacist. ➤ <u>Dr. Benjamin Miles, Vice Chair, DC Board of Pharmacy</u> also agrees and states that <i>"it would be very difficult to get some sort of consistent training during your last year of pharmacy school when you're already on rotations full time and potentially working in a pharmacy only...having graduated would be important because then you can focus on the training [] after you've graduated."</i> ➤ <u>Dr. Allison Hill, Board Chair, DC Board of Pharmacy</u> agrees and states that the training required for the pharmacist-in-charge, including knowing how to complete records, knowing how to manage [staff], while not gaining first-hand experience, [could not] be completed before [licensure as a pharmacist]. • <u>Dr. Grace Sesi, CVS Health</u> follows up by asking <i>"Is this something that would be clarified in their rule or is this something that will be an FAQ or is this official in terms of after graduation versus licensure or still under consideration?"</i> <ul style="list-style-type: none"> ➤ <u>Board Counsel, Ms. Carla Williams</u>, states that the Pharmaceutical Control Division <i>"clarifies it in the rule."</i> • <u>Dr. Grace Sesi, CVS Health</u> asks: regarding the section on a pharmacist-in-charge reporting robberies <i>"I just also still want to clarify if this is a front store employee – the cashier that never worked in the pharmacy – and</i> 	

	<p><i>if there is a theft in terms of a coke, the Board of Pharmacy still wants this reported?"</i></p> <ul style="list-style-type: none"> ➤ <u>Board Counsel, Ms. Carla Williams</u>, responds by stating <i>"We're talking about an employee who has the potential to either be working in the pharmacy, filling in when you're short staffed, or just some other way, go back there and cause a diversion, diversion or theft to occur. And we [] clarify that it's only after discovery; only if you are aware of it and when you become aware of it."</i> • <u>Dr. Marci Baloga, Safeway Pharmacy</u> asks as a follow up to Dr. Sesi's question: <i>"If [an employee] [has] been identified as having a theft on the front end, [does the Board] also want that reported [] as well, even though it wasn't a theft of drug product, if it was a theft of any sort, [it must be] reported."</i> ➤ <u>Executive Director of the DC Board of Pharmacy, Dr. Justin Ortique</u> responds <i>"Yes, that is correct."</i> 	
<p><u>Motion to Adjourn the Open Session</u></p>	<p>Board member, Dr. Benjamin Miles, moved the Board as follows:</p> <p>"Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve settlement agreements pursuant to § 2-575(b)(4); and to plan, discuss, or hear reports concerning ongoing or planned investigations pursuant to § 2-575(b)(14)."</p> <p>Seconded by: Board Member, Dr. Jamila Jorden.</p> <p>Roll Call Vote:</p> <p>Dr. Benjamin Miles: Voted in favor of the motion. Dr. Jamila Jorden: Voted in favor of the motion. Mr. Roderick McGill: Voted in favor of the motion.</p>	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at 10:25 AM.

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.